GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Poolbeg Pharma PLC (LSE:POLB) » Definitions » EV-to-EBIT

Poolbeg Pharma (LSE:POLB) EV-to-EBIT : -0.86 (As of Apr. 26, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Poolbeg Pharma EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Poolbeg Pharma's Enterprise Value is £4.44 Mil. Poolbeg Pharma's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was £-5.13 Mil. Therefore, Poolbeg Pharma's EV-to-EBIT for today is -0.86.

The historical rank and industry rank for Poolbeg Pharma's EV-to-EBIT or its related term are showing as below:

LSE:POLB' s EV-to-EBIT Range Over the Past 10 Years
Min: -0.72   Med: 0   Max: 0
Current: -0.87

LSE:POLB's EV-to-EBIT is ranked worse than
100% of 489 companies
in the Biotechnology industry
Industry Median: 6.51 vs LSE:POLB: -0.87

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Poolbeg Pharma's Enterprise Value for the quarter that ended in Jun. 2024 was £54.94 Mil. Poolbeg Pharma's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was £-5.13 Mil. Poolbeg Pharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -9.34%.


Poolbeg Pharma EV-to-EBIT Historical Data

The historical data trend for Poolbeg Pharma's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Poolbeg Pharma EV-to-EBIT Chart

Poolbeg Pharma Annual Data
Trend Dec21 Dec22 Dec23
EV-to-EBIT
-11.37 -2.82 -7.06

Poolbeg Pharma Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EV-to-EBIT Get a 7-Day Free Trial - -2.82 - -7.06 -

Competitive Comparison of Poolbeg Pharma's EV-to-EBIT

For the Biotechnology subindustry, Poolbeg Pharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Poolbeg Pharma's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Poolbeg Pharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Poolbeg Pharma's EV-to-EBIT falls into.


;
;

Poolbeg Pharma EV-to-EBIT Calculation

Poolbeg Pharma's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=4.439/-5.132
=-0.86

Poolbeg Pharma's current Enterprise Value is £4.44 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Poolbeg Pharma's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was £-5.13 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Poolbeg Pharma  (LSE:POLB) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Poolbeg Pharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2024 ) =EBIT / Enterprise Value (Q: Jun. 2024 )
=-5.132/54.939
=-9.34 %

Poolbeg Pharma's Enterprise Value for the quarter that ended in Jun. 2024 was £54.94 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Poolbeg Pharma's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was £-5.13 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Poolbeg Pharma EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Poolbeg Pharma's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Poolbeg Pharma Business Description

Traded in Other Exchanges
Address
42 New Road, Queen Mary BioEnterprises Innovation Centre, London, GBR, E1 2AX
Poolbeg Pharma PLC is a clinical-stage infectious disease pharmaceutical company, with a novel capital-light clinical model which enables to develop of multiple products faster and more cost-effectively than the traditional biotech model. The company aspires to become a one-stop shop for pharma-seeking mid-stage products to license or acquire.

Poolbeg Pharma Headlines

No Headlines